TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39538176
Drug: Sonidegib 200
Normalized name: sonidegib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonidegib 200 mg orally once daily
Study: 39538331
Drug: Neoantigen DNA
Normalized name: Toxoplasma gondii DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoantigen DNA vaccine administered via electroporation, three doses encoding an average of 11 neoantigens per patient (range 4-20).
Study: 39539144
Drug: Triazavirin (TZV)
DrugBank: Triazavirin (DB15622)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazavirin (TZV) 250 mg capsules three-times daily for 7 days
Study: 39539144
Drug: Oseltamivir 75
Normalized name: oseltamivir 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir 75 mg capsules twice per day for 7 days
Study: 39539664
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with anticoagulants and antiplatelet agents
Study: 39540459
Drug: My Grief
Approvals — FDA: no, EMA: no, PMDA: no
Description: My Grief app (based on cognitive-behavioural therapy)
Study: 39540661
Drug: Sunitinib (37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (37.5 mg/day on days 1-14, 25 mg/day afterward) plus nivolumab (3 mg/kg every 2 weeks)
Study: 39540734
Drug: Isavuconazonium sulfate
Normalized name: Isavuconazonium Sulfate
DrugBank: Isavuconazonium (DB06636)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Isavuconazonium sulfate 10 mg/kg daily (maximum 372 mg; equivalent to 5.4 mg/kg or 200 mg isavuconazole) for up to 84 days (IA) or 180 days (IM)
Study: 39540734
Drug: Isavuconazonium sulfate
Normalized name: Isavuconazonium Sulfate
DrugBank: Isavuconazonium (DB06636)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Isavuconazonium sulfate 10 mg/kg daily
Study: 39540734
Drug: Simulated doses
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simulated doses of 15 mg/kg
Study: 39540799
Drug: Standard care:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care: TDF starting at gestational week 28 with HBV vaccinations and HBIG administered to the infant
Study: 39540934
Drug: safinamide 100
Normalized name: safinamide 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: safinamide 100 mg/day after 2 weeks of 50 mg/day
Study: 39541202
Drug: Toripalimab plus
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab plus etoposide and platinum-based chemotherapy (EP)
Study: 39541202
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus etoposide and platinum-based chemotherapy (EP)
Study: 39541755
Drug: L test
Normalized name: CHOLESTEROL TEST
Approvals — FDA: no, EMA: no, PMDA: no
Description: L test
Study: 39542642
Drug: L-TAP block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-TAP block
Study: 39542995
Drug: Sovateltide (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sovateltide (0.3 µg/kg) administered intravenously in three doses at 3 ± 1 h intervals on Days 1, 3, and 6.
Study: 39543001
Drug: 300-mg BUP-XR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300-mg BUP-XR injection in the upper arm
Study: 39543001
Drug: 300-mg BUP-XR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300-mg BUP-XR injection in the thigh
Study: 39543001
Drug: 300-mg BUP-XR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300-mg BUP-XR injection in the buttocks
Study: 39543001
Drug: 300-mg BUP-XR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300-mg BUP-XR injection in the abdomen (reference)
Study: 39543001
Drug: Safety evaluations
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety evaluations including treatment-emergent adverse events and assessments of injection site pain, tenderness, erythema, induration, and swelling
Study: 39543340
Drug: NEIVATECH system
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEIVATECH system (9 hours of therapy, 18 half-hour sessions over 1 month)
Study: 39544014
Drug: Ergothioneine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ergothioneine (25 mg per capsule, taken 3 times a week for one year)
Study: 39544430
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of NabPaclitaxel-PIPAC and systemic NabPaclitaxel-Gemcitabine
Study: 39545610
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus PD-1 inhibitor and radiotherapy
Study: 39545967
Drug: Once-daily iTBS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily iTBS
Study: 39545967
Drug: Twice-daily iTBS
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily iTBS
Study: 39546040
Drug: Almond consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almond consumption (50 g daily)
Study: 39546477
Drug: Immediate office-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate office-based vergence/accommodative therapy with movement (OBVAM)
Study: 39547230
Drug: High-dose AAV8.TBG.hARSB
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose AAV8.TBG.hARSB gene therapy (single intravenous infusion)
Study: 39547249
Drug: FYTF-919 (Zhongfeng
Approvals — FDA: no, EMA: no, PMDA: no
Description: FYTF-919 (Zhongfeng Xingnao) oral solution, 33 mL every 8 hours for 28 days (or 25 mL via nasogastric tube if swallowing impaired)
Study: 39547249
Drug: Placebo, matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, matching appearance and administration as FYTF-919
Study: 39547832
Drug: Bioresorbable vascular
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioresorbable vascular scaffold (BVS) implantation with prolonged dual antiplatelet therapy (DAPT) for 36 months
Study: 39547981
Drug: Lipid-lowering drug
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering drug targets gene variants (specific SNPs not detailed)
Study: 39548306
Drug: G-CSF only
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF only (G)
Study: 39548306
Drug: Standard chemotherapy/G-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy/G-CSF (CG)
Study: 39548607
Drug: Illioinguinal/iliohypogastric nerve
Approvals — FDA: no, EMA: no, PMDA: no
Description: Illioinguinal/iliohypogastric nerve block with 20 ml of 0.25% ropivacaine
Study: 39548607
Drug: Wound infiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wound infiltration with 10 ml of 0.25% ropivacaine
Study: 39549554
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of spermidine, nicotinamide, PEA, and OEA supplements
Study: 39549554
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose of spermidine, nicotinamide, PEA, and OEA supplements
Study: 39549554
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of spermidine, nicotinamide, PEA, and OEA supplements
Study: 39549554
Drug: All supplement
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All supplement doses combined
Study: 39549719
Drug: Setmelanotide (subcutaneous,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Setmelanotide (subcutaneous, once daily for 52 weeks, starting at 0.5 mg with increments of 0.5 mg every 2 weeks)
Study: 39549720
Drug: HIPEC (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIPEC (cisplatin 75 mg/m²)
Study: 39549817
Drug: Biologics (CD:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologics (CD: 73.2%, UC: 30.3%)
Study: 39549817
Drug: Immunosuppressants (CD:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunosuppressants (CD: 65.3%, UC: 58.6%)
Study: 39550721
Drug: Finerenone (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finerenone (titrated to 20 mg or 40 mg)
Study: 39551007
Drug: Adjunct dextromethorphan
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunct dextromethorphan (30 mg)
Study: 39551007
Drug: Adjunct placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunct placebo
Study: 39551057
Drug: Community-based screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based screening and treatment for Chlamydia trachomatis and Neisseria gonorrhoeae (males and females) and Trichomonas vaginalis (females only) offered over 12 months.
Study: 39551057
Drug: Community-based screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based screening and treatment for Chlamydia trachomatis and Neisseria gonorrhoeae.
Study: 39551057
Drug: Community-based screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based screening and treatment for Trichomonas vaginalis.
Study: 39551057
Drug: Community-based screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based screening and treatment for Neisseria gonorrhoeae.
Study: 39551062
Drug: MDA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDA with dihydroartemisinin-piperaquine and ivermectin (300 μg/kg per day)
Study: 39551064
Drug: Durvalumab 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab 1500 mg starting 2 weeks before radiotherapy then every 4 weeks starting week 2 of radiotherapy (seven cycles)
Study: 39551064
Drug: Cetuximab 400
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab 400 mg/m2
Study: 39551132
Drug: Apixaban, 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban, 2.5 mg twice daily for three months
Study: 39551147
Drug: HIV prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV prevention intervention as treatment per usual (active control)
Study: 39551147
Drug: Weekly PrEP
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly PrEP adherence assessments
Study: 39551356
Drug: Complementary dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary dietary fibers (total dietary fiber - complementary foods (g))
Study: 39551469
Drug: Deulorlatinib 60
Normalized name: LORLATINIB
DrugBank: Lorlatinib (DB12130)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Deulorlatinib 60 mg once per day (recommended phase 2 dose)
Study: 39551600
Drug: MEDI5395 (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI5395 (recombinant attenuated Newcastle disease virus) administered intravenously as six doses over 15-18 days
Study: 39551600
Drug: Durvalumab (anti-PD-L1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (anti-PD-L1 immune checkpoint inhibitor)
Study: 39551735
Drug: Three daily
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three daily assessments of depressive symptoms across one menstrual cycle
Study: 39551791
Drug: HTNV DNA
Normalized name: HTNV DNA vaccine
DrugBank: Hantaan virus DNA vaccine (DB17808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTNV DNA vaccine (2 mg/vaccination)
Study: 39551791
Drug: PUUV DNA
Normalized name: PUUV DNA vaccine
DrugBank: Puumala virus DNA vaccine (DB17809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUUV DNA vaccine (2 mg/vaccination)
Study: 39551791
Drug: Combined HTNV/PUUV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined HTNV/PUUV DNA vaccine (2 mg/vaccination of 1:1 mixture)
Study: 39551791
Drug: HTNV DNA
Normalized name: HTNV DNA vaccine
DrugBank: Hantaan virus DNA vaccine (DB17808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTNV DNA vaccine
Study: 39551791
Drug: PUUV DNA
Normalized name: PUUV DNA vaccine
DrugBank: Puumala virus DNA vaccine (DB17809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PUUV DNA vaccine
Study: 39552638
Drug: 2LM niraparib
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2LM niraparib monotherapy
Study: 39554834
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus brief healthy diet and exercise education (MET+LIFE)
Study: 39555642
Drug: Laughter yoga
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Laughter yoga (twice a week for 35-40 minutes, six sessions total)
Study: 39555818
Drug: Oral infigratinib
Normalized name: infigratinib
DrugBank: Infigratinib (DB11886)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral infigratinib at 0.25 mg/kg for 18 months (cohort 5)
Study: 39555820
Drug: Antiarrhythmic drug
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic drug therapy (sotalol or amiodarone)
Study: 39555826
Drug: Tirzepatide (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirzepatide (up to 15 mg subcutaneously once per week)
Study: 39556016
Drug: RP-A501 infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RP-A501 infusion with transient immunomodulatory regimen (prednisone, tacrolimus or sirolimus, and rituximab)
Study: 39556016
Drug: RP-A501 infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RP-A501 infusion
Study: 39556397
Drug: Baby Hand-Arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baby Hand-Arm Bimanual Intensive Therapy Including Lower Extremities (HABIT-ILE), 50 hours over 2 weeks
Study: 39556768
Drug: Muvalaplin 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muvalaplin 10 mg/d
Study: 39556768
Drug: Muvalaplin 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muvalaplin 60 mg/d
Study: 39556768
Drug: Muvalaplin 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muvalaplin 240 mg/d
Study: 39556769
Drug: Zerlasiran 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zerlasiran 450 mg every 24 weeks for 2 doses
Study: 39556769
Drug: Zerlasiran 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zerlasiran 300 mg every 16 weeks for 3 doses
Study: 39556769
Drug: Zerlasiran 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zerlasiran 300 mg every 24 weeks for 2 doses
Study: 39556769
Drug: Placebo (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (subcutaneous dose every 16 weeks for 3 doses or every 24 weeks for 2 doses)
Study: 39556772
Drug: Secretin infusion
Normalized name: Secretin
DrugBank: Secretin human (DB09532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Secretin infusion (1 pmol/kg/min)
Study: 39557109
Drug: Apixaban +
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apixaban + aspirin
Study: 39557109
Drug: Warfarin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin + aspirin
Study: 39557109
Drug: Apixaban vs.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban vs. Warfarin
Study: 39557109
Drug: Aspirin vs.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin vs. Placebo
Study: 39557487
Drug: Fezolinetant 45
Normalized name: fezolinetant 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fezolinetant 45 mg once daily for 24 weeks
Study: 39557549
Drug: mHealth treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: mHealth treatment (audio-only mobile phone)
Study: 39557557
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of acetylsalicylic acid daily (LDA)
Study: 39557997
Drug: Daily circadian
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily circadian phase shifts
Study: 39558280
Drug: Group Antenatal
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Antenatal Care (G-ANC)
Study: 39558302
Drug: Daily assessments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily assessments via the patientMpower app including handheld spirometry and exercise tests.
Study: 39558601
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of analgesics
Study: 39560075
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (high-dose greater than 1000 mg/day)
Study: 39560398
Drug: CIH therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIH therapies (n = 140)
Study: 39560548
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination (FDC) of PG201 (405.4 mg) and celecoxib (100 mg)
Study: 39560548
Drug: Individual formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual formulations of PG201 and celecoxib
Study: 39560548
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination (FDC) of PG201 and celecoxib
Study: 39560548
Drug: Both FDC
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both FDC and individual formulations
Study: 39560771
Drug: Prophylactic dose
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic dose of enoxaparin starting at 0.5 mg/kg adjusted to anti-Xa range of 0.2-0.5 IU/mL for older children
Study: 39560771
Drug: Therapeutic dose
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic dose of enoxaparin starting at 1.5 mg/kg adjusted to anti-Xa range of greater than 0.5-1.0 IU/mL or 0.2-0.5 IU/mL for infants
Study: 39560862
Drug: Adavosertib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adavosertib (150 mg bid for 3 days on/4 days off) plus Durvalumab (1500 mg Q4W)
Study: 39560862
Drug: Adavosertib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adavosertib (300 mg qd for 5 days on/2 days off) plus Durvalumab (1500 mg Q4W)
Study: 39561184
Drug: Single-dose albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose albendazole (ALB)
Study: 39561225
Drug: Alirocumab 150
Normalized name: alirocumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alirocumab 150 mg biweekly in addition to high-intensity statins
Study: 39561281
Drug: dVHH NS7CAR-T
Normalized name: T-5224
DrugBank: T-5224 (DB05998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dVHH NS7CAR-T cells (dosage levels: 5×10^5/kg and 1×10^6/kg)
Study: 39561384
Drug: UGN-101 (mitomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: UGN-101 (mitomycin reverse thermal gel)
Study: 39561689
Drug: PS-enriched soy
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: PS-enriched soy milk (2 g/day)
Study: 39563311
Drug: Home-based rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based rehabilitation exercise using elastic bands (performed exercise dose measured in repetitions/week)
Study: 39563457
Drug: Comparator (rabies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator (rabies vaccine)
Study: 39563465
Drug: FC-FORT intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: FC-FORT intervention (7 consecutive weeks of virtual group therapy and homework)
Study: 39565030
Drug: 7 days
Normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days of antibiotic treatment (per-protocol analysis)
Study: 39565030
Drug: 14 days
Normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 14 days of antibiotic treatment (per-protocol analysis)
Study: 39565228
Drug: Secukinumab (SEC)
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Secukinumab (SEC) 300 mg s.c. administered regularly until week 16, followed by randomization to SEC or placebo up to week 32.
Study: 39565228
Drug: Placebo after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo after SEC treatment.
Study: 39565228
Drug: Secukinumab (SEC)
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Secukinumab (SEC) treatment.
Study: 39565449
Drug: Lactoferrin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactoferrin (100 mg/day for 4 weeks or until discharge)
Study: 39565495
Drug: Vepdegestrant 200
Normalized name: Vepdegestrant
DrugBank: Vepdegestrant (DB19006)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vepdegestrant 200 mg once daily (QD)
Study: 39565495
Drug: Vepdegestrant 200
Normalized name: Vepdegestrant
DrugBank: Vepdegestrant (DB19006)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vepdegestrant 200 mg QD
Study: 39565570
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pembrolizumab plus radium-223
Study: 39565703
Drug: Mandala coloring
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mandala coloring for a minimum of 30 minutes during and after chemotherapy treatment.
Study: 39565908
Drug: Grade 1-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grade 1-2 treatment-related irAEs
Study: 39565908
Drug: Grade 3-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grade 3-4 treatment-related irAEs
Study: 39565980
Drug: Middle meningeal
Normalized name: wheat middlings extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Middle meningeal artery embolization (adjunct to standard treatment)
Study: 39566128
Drug: Promestriene treatment
Normalized name: promestriene
DrugBank: Promestriene (DB12487)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promestriene treatment (Control)
Study: 39566464
Drug: Durvalumab with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab with chemotherapy
Study: 39566600
Drug: Low-carbohydrate diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-carbohydrate diet (LCD) - 75 g carbohydrates for 8 weeks
Study: 39566600
Drug: Low-fat diet
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat diet (LED) - 180 g carbohydrates for 8 weeks
Study: 39567210
Drug: IO-108 monotherapy
Normalized name: Io-Shield
Approvals — FDA: no, EMA: no, PMDA: no
Description: IO-108 monotherapy
Study: 39567210
Drug: IO-108 monotherapy
Normalized name: Io-Shield
Approvals — FDA: no, EMA: no, PMDA: no
Description: IO-108 monotherapy and combination therapy
Study: 39567211
Drug: Nemvaleukin alfa
Normalized name: Nemvaleukin alfa
DrugBank: Nemvaleukin alfa (DB18187)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemvaleukin alfa monotherapy (6 µg/kg/day)
Study: 39567211
Drug: Nemvaleukin alfa
Normalized name: Nemvaleukin alfa
DrugBank: Nemvaleukin alfa (DB18187)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemvaleukin alfa (dose-escalation)
Study: 39568009
Drug: Modified Kasai
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Kasai operation combined with autologous bone marrow mononuclear cell (BMMNC) infusion
Study: 39568724
Drug: 18 g sunflower
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 g sunflower lecithin (LPL)